Skip to main content

Table 1 Clinical-pathological data of breast cancer patients included in the study

From: Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis

Patient number Age ER (%) PR (%) HER2 (+/−) Ki67 (%) Grade Tumor size LN mets Anti-hormonal therapy
1 62 95 70 5 1 pT1b pN1a
2 58 95 95 10 2 T1b N0
3 50 100 100 + 5 1 pT1 pN0 Tamoxifen
4 73 95 2 25 2 pT2 pN1a
5 49 90 80 10 2 T1b pN0 Tamoxifen
6 69 100 100 15 2 pT1a pN0 Tamoxifen
7 53 95 60 10 2 pT1c pN0 Letrozole
8 73 100 0 20 na pT1c pN0 Tamoxifen
9 67 90 80 5 1 pT1b pN0 Tamoxifen
10 66 100 100 5 2 pT1c pN0 Letrozole
11 64 95 80 10 1 pT1b pN0 Letrozole
12 61 80 100 10 2 pT1b pN0 Anastrozole
13 43 95 95 10 2 pT1c pN0 Tamoxifen
  1. Patient’s demographics, tumor subtype, grade, stage (pT and pN), and anti-hormonal treatment after conservative surgery. ER (%), estrogen receptor expression in percent; PR (%), progesterone receptor expression in percent; HER2 (±), overexpression of HER-2; Ki67 (%), fraction of cancer cells positive for Ki67 expression